Gustavo Velasquez, MD, MPH

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address1001 Potrero Avenue
San Francisco CA 94110
ORCID ORCID Icon0000-0003-1438-0692 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford UniversityBAS2004
    Northwestern University Feinberg School of MedicineMD2009
    Harvard T.H. Chan School of Public HealthMPH2009Quantitative Methods and Infectious Disease Epidemiology
    Brigham and Women's HospitalResidency2013Internal Medicine and Global Health Equity
    Massachusetts General Hospital and Brigham and Women's HospitalFellowship2015Infectious Diseases
    University of California, San Francisco2022Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse Overview
    Dr. Velásquez is an Assistant Professor of Medicine in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco. He is an infectious disease physician and clinical researcher focused on the development of treatment regimens for drug-susceptible and drug-resistant tuberculosis (TB), with a special interest in the safety and tolerability of TB treatment. He works with the endTB consortium ( and serves as a co-investigator in two multi-country Phase 3 randomized controlled clinical trials evaluating novel shortened oral regimens for multidrug-resistant TB (MDR-TB), specifically fluoroquinolone-susceptible MDR-TB (endTB, NCT02754765) and fluoroquinolone-resistant MDR-TB (endTB-Q, NCT03896685), and in the trials’ pharmacokinetic and pharmacodynamic (PK/PD) sub-study (PandrTB, NCT03827811). He is supported by an NIH/NIAID Mentored Clinical Scientist Research Career Development Award (K08 AI141740) which leverages his role in the trials above to examine the safety, tolerability, and PK/PD of new and repurposed drugs for MDR-TB. Dr. Velásquez serves as an Investigator in the AIDS Clinical Trials Group’s TB Transformative Science Group. He attends on the inpatient ID service and outpatient HIV and TB clinics at San Francisco General Hospital.

    Collapse Research 
    Collapse Research Activities and Funding
    Safety and tolerability of new and repurposed drugs for MDR-TB treatment
    NIH K08AI141740Feb 1, 2019 - Jan 31, 2024
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru. BMC Infect Dis. 2023 Feb 02; 23(1):62. Law S, Tovar MA, Franke MF, Calderon R, Palomino S, Valderrama G, Llanos F, Velásquez GE, Mitnick CD, Lecca L. PMID: 36732690; PMCID: PMC9893955.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    2. Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-Susceptible Tuberculosis. Am J Respir Crit Care Med. 2023 Jan 11. Vel?squez GE, Nahid P. PMID: 36630555.
      View in: PubMed   Mentions:    Fields:    
    3. Clinical Outcomes of Individuals with COVID-19 and Tuberculosis during the Pre-Vaccination Period of the Pandemic: A Systematic Review. J Clin Med. 2022 Sep 26; 11(19). Jhaveri TA, Fung C, LaHood AN, Lindeborg A, Zeng C, Rahman R, Bain PA, Vel?squez GE, Mitnick CD. PMID: 36233523; PMCID: PMC9570663.
      View in: PubMed   Mentions:
    4. Diagnostic Performance Assessment of Saliva RT-PCR and Nasopharyngeal Antigen for the Detection of SARS-CoV-2 in Peru. Microbiol Spectr. 2022 08 31; 10(4):e0086122. Calderón RI, Jhaveri TA, Tovar MA, Palomino JS, Barreda NN, Sanabria OM, Peinado J, Ramirez C, Llanos Zavalaga LF, Valderrama G, Franke MF, Mitnick CD, Lecca L, Velásquez GE. PMID: 35867471; PMCID: PMC9430815.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    5. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Market and City Bus Depot Workers in Lima, Peru. Clin Infect Dis. 2022 01 29; 74(2):343-346. Tovar M, Peinado J, Palomino S, Llanos F, Ram?rez C, Valderrama G, Calder?n RI, Williams RB, Vel?squez GE, Mitnick CD, Franke MF, Lecca L. PMID: 33881476; PMCID: PMC8083218.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    6. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651. Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Vel?squez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD. PMID: 34563240; PMCID: PMC8465691.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    7. Disparities in SARS-CoV-2 Vaccination-to-Infection Risk During the COVID-19 Pandemic in Massachusetts. JAMA Health Forum. 2021 09; 2(9):e212666. Dryden-Peterson S, Vel?squez GE, Stopka TJ, Davey S, Gandhi RT, Lockman S, Ojikutu BO. PMID: 35977180; PMCID: PMC8796904.
      View in: PubMed   Mentions: Translation:HumansCellsPHPublic Health
    8. Disparities in SARS-CoV-2 Vaccination-to-Infection Risk, Massachusetts 2020-2021. medRxiv. 2021; 2021.04.14.21255467.2021. Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Gandhi RT, Lockman S, Ojikutu BO. View Publication.
    9. Disparities in SARS-CoV-2 Testing in Massachusetts During the COVID-19 Pandemic. JAMA Netw Open. 2021 02 01; 4(2):e2037067. Dryden-Peterson S, Vel?squez GE, Stopka TJ, Davey S, Lockman S, Ojikutu BO. PMID: 33560423; PMCID: PMC7873783.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsPHPublic Health
    10. SARS-CoV-2 Testing Disparities in Massachusetts. medRxiv. 2020 Nov 04. Dryden-Peterson S, Vel?squez GE, Stopka TJ, Davey S, Lockman S, Ojikutu B. PMID: 33173919; PMCID: PMC7654915.
      View in: PubMed   Mentions:
    11. Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series. Open Forum Infect Dis. 2020 Oct; 7(10):ofaa415. Pearson JC, Dionne B, Richterman A, Vidal SJ, Weiss Z, Vel?squez GE, Marty FM, Sax PE, Yawetz S. PMID: 33094118; PMCID: PMC7566545.
      View in: PubMed   Mentions: 10  
    12. Delayed Relapse of Paracoccidioidomycosis in the Central Nervous System: A Case Report. Open Forum Infect Dis. 2020 Apr; 7(4):ofaa077. Rahman R, Davies L, Mohareb AM, Pe?anha-Pietrobom PM, Patel NJ, Solomon IH, Meredith DM, Tsai HK, Guenette JP, Bhattacharyya S, Urday S, Vel?squez GE. PMID: 32258208; PMCID: PMC7112725.
      View in: PubMed   Mentions: 4  
    13. The fourth national anti-tuberculosis drug resistance survey in Peru. Int J Tuberc Lung Dis. 2020 02 01; 24(2):207-213. Quispe N, Asencios L, Obregon C, Vel?squez GE, Mitnick CD, Lindeborg M, Jave H, Solari L. PMID: 32127106; PMCID: PMC7325691.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    14. Quantitative assessment of the activity of antituberculosis drugs and regimens. Expert Rev Anti Infect Ther. 2019 06; 17(6):449-457. Chirehwa MT, Vel?squez GE, Gumbo T, McIlleron H. PMID: 31144539; PMCID: PMC6581212.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    15. Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis. Am J Respir Crit Care Med. 2019 05 01; 199(9):1167-1168. Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD. PMID: 30645140; PMCID: PMC6515881.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Outcomes of a Career Development Program for Underrepresented Minority Investigators in the AIDS Clinical Trials Group. Open Forum Infect Dis. 2019 Mar; 6(3):ofz069. Vel?squez GE, Huaman MA, Powell KR, Cohn SE, Swaminathan S, Outlaw M, Schulte G, McNeil Q, Currier JS, Del Rio C, Castillo-Mancilla J. PMID: 30895207; PMCID: PMC6419986.
      View in: PubMed   Mentions: 2  
    17. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 09 01; 198(5):657-666. Vel?squez GE, Brooks MB, Coit JM, Pertinez H, Vargas V?squez D, S?nchez Garavito E, Calder?n RI, Jim?nez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD. PMID: 29954183; PMCID: PMC6118011.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    18. Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis. Int J Tuberc Lung Dis. 2018 05 01; 22(5):473-474. Vel?squez GE, Davies GR, Mitnick CD. PMID: 29663947; PMCID: PMC5940349.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept. J Gen Intern Med. 2018 05; 33(5):769-772. Jain N, Doyon JB, Lazarus JE, Schaefer IM, Johncilla ME, Agoston AT, Dalal AK, Velásquez GE. PMID: 29532302; PMCID: PMC5910370.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    20. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. Int J Tuberc Lung Dis. 2017 08 01; 21(8):894-901. Calder?n RI, Vel?squez GE, Becerra MC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Kritski AL, Murray MB, Mitnick CD. PMID: 28786798; PMCID: PMC5555119.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother. 2017 08; 61(8). Peloquin CA, Vel?squez GE, Lecca L, Calder?n RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G. PMID: 28559269; PMCID: PMC5527578.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    22. Nutritional Status and Tuberculosis Risk in Adult and Pediatric Household Contacts. PLoS One. 2016; 11(11):e0166333. Aibana O, Acharya X, Huang CC, Becerra MC, Galea JT, Chiang SS, Contreras C, Calderon R, Yataco R, Vel?squez GE, Tintaya K, Jimenez J, Lecca L, Murray MB. PMID: 27835678; PMCID: PMC5105945.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    23. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2016 11; 60(11):6766-6773. Vel?squez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB. PMID: 27600032; PMCID: PMC5075084.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    24. Novel Ordered Stepped-Wedge Cluster Trial Designs for Detecting Ebola Vaccine Efficacy Using a Spatially Structured Mathematical Model. PLoS Negl Trop Dis. 2016 08; 10(8):e0004866. Diakite I, Mooring EQ, Velásquez GE, Murray MB. PMID: 27509037; PMCID: PMC4979980.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    25. Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study. BMC Infect Dis. 2016 Feb 01; 16:45. Vel?squez GE, Cegielski JP, Murray MB, Yagui MJ, Asencios LL, Bayona JN, Bonilla CA, Jave HO, Yale G, Su?rez CZ, Sanchez E, Rojas C, Atwood SS, Contreras CC, Santa Cruz J, Shin SS. PMID: 26831140; PMCID: PMC4736097.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Time From Infection to Disease and Infectiousness for Ebola Virus Disease, a Systematic Review. Clin Infect Dis. 2015 Oct 01; 61(7):1135-40. Vel?squez GE, Aibana O, Ling EJ, Diakite I, Mooring EQ, Murray MB. PMID: 26129757; PMCID: PMC4560911.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsPHPublic Health
    27. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014 Jul 01; 59(1):9-15. Vel?squez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S. PMID: 24729493; PMCID: PMC4305127.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    28. Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008. Emerg Infect Dis. 2011 Mar; 17(3):432-40. Vel?squez GE, Yagui M, Cegielski JP, Asencios L, Bayona J, Bonilla C, Jave HO, Yale G, Su?rez C, Atwood S, Contreras CC, Shin SS. PMID: 21392434; PMCID: PMC3166030.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsPHPublic Health
    Gustavo's Networks
    Concepts (99)
    Derived automatically from this person's publications.
    Co-Authors (4)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department